Edition:
United Kingdom

Bergenbio ASA (BGBIO.OL)

BGBIO.OL on Oslo Stock Exchange

16.50NOK
3:25pm BST
Change (% chg)

kr2.02 (+13.95%)
Prev Close
kr14.48
Open
kr15.10
Day's High
kr19.90
Day's Low
kr15.10
Volume
2,269,684
Avg. Vol
64,807
52-wk High
kr40.00
52-wk Low
kr11.50

Summary

Name Age Since Current Position

Sveinung Hole

2019 Chairman of the Board

Richard Godfrey

51 2008 Chief Executive Officer

Rune Skeie

44 2018 Chief Financial Officer

Endre Kjaerland

Associate Director of IP and Contracts

Julia Schoelermann

Collaboration Manager

Dominic Smethurst

2019 Chief Medical Officer

Victoria Wills

2016 Director of Clinical Operations

Debra Barker

2019 Non-Executive Director

Grunde Eriksen

2019 Non-Executive Director

Pamela Trail

2019 Non-Executive Director

Stener Kvinnsland

2015 Non-Executive Independent Director

Biographies

Name Description

Sveinung Hole

Mr. Sveinung Hole has served as Chairman of the Board of Bergenbio ASA since March 13, 2019. He has previously been Non-Executive Director of Bergenbio ASA since February 1, 2016. Sveinung Hole is the CEO of Bergen Research Foundation and the Kristian Gerhard Jebsen Foundation. Hole holds a number of Board positions amongst others at Sarsia Seed AS, Norwegian Venture Capital Association, Prophylix Pharma AS and VoluSense AS. Formerly, he was the CEO of the investment fund Sarsia Seed AS, Board Member of Bergen Hospital Trust (Helse Bergen) and Director of Anesthesia and Intensive Care at Haukeland University Hospital. Hole has also held various top management positions (Market, Strategy, Internet) at Telenor Corporation and been Regional Managing Director/Director of Global Strategies at the Berlitz Corporation. Hole holds a Master of International Management from BI Norwegian Business School. He serves at Pe Helse AS (chairman), Volusense AS (chairman), Nordic And Europe Health Invest AS (board member), Sarsia Seed AS (board member), Bergen Research Foundation (CEO), the Kristian Gerhard Jebsen Foundation (CEO) Prophylix Pharma AS (board member), Sarsia Seed Fond II AS (chairman) Tromso Forskningsstiftelse (board member). He previously was employed at Sarsia Seed Management (managing partner), Isentio AS (board member), Stiftelsesforvaltning AS (board member), Norwegian Venture Capital Association (board member), Bergen Hospital Trust (Helse Bergen) (board member), Nansen Neuroscience Network (board member) and BerGenBio AS (board member).

Richard Godfrey

Mr. Richard S. Godfrey has served as Chief Executive Officer (CEO) of Bergenbio ASA since 2008. He has more than 28 years’ industry experience leading many international drug development and commercialization partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in R&D and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University. He serves at Square One Holding AS (board member), Gnist Holding AS (managing director and chairman), Magnet Strategy and marketing Partners AS (board member), Biotec Pharmacon ASA (board member), Balter Medical AS (board member), Uni Targeting Research AS (chairman), Petosan AS (chairman) and Gnist Ltd (director). He was previously employed at Sarisa Venture management (board member and partner), Ayanda Group AS (board member) and Captech AS (board member).

Rune Skeie

Mr. Rune Skeie has been Chief Financial Officer at BERGENBIO ASA since March 5, 2018. He has over 20 years of financial management, corporate development, corporate governance and advisory experience with public and private companies across multiple industry sectors. The majority of his career was spent at EY (formerly Ernst & Young), where he held the role of Executive Director, before joining REMA Franchise Norge AS, the multinational supermarket business, as CFO. Mr. Skeie is a Registered Accountant and a State Authorized Public Accountant.

Endre Kjaerland

Dr. Endre Kjaerland serves as Associate Director of IP and Contracts at BERGENBIO ASA. He joined BerGenBio AS in 2011 and is now head of intellectual property, quality systems and contracts. Prior to joining BerGenBio, he has gained more than 10 years of experience in academic science and supervision. He completed a Master of Science in molecular biology and Ph.D. in biochemistry from the University of Bergen.

Julia Schoelermann

Dr. Julia Schoelermann serves as Collaboration Manager at BERGENBIO ASA. She joined BerGenBio in 2015 in a business support role. She brings 10 years of hands-on laboratory and academic supervision experience from top European research institutions. Alongside she has worked several years as entrepreneurship community leader, advising IT and biotech startups as well as running own technology projects. She holds a Master of Science in biotechnology and biophysics from the University of Heidelberg as well as a Ph.D. in cell biology from the University of Bergen.

Dominic Smethurst

Dr. Dominic Smethurst has been Chief Medical Officer at BERGENBIO ASA since March 14, 2019. Dominic trained as a physician in Cambridge and Nottingham and brings two decades of experience in clinical development and leadership roles within the biopharma industry and leading consultancies including AstraZeneca, Amgen, Prescient Life Sciences and ICON. Most recently, he served as CMO at Tusk Therapeutics Ltd, an immune-oncology biotech which was acquired by Roche in 2018.

Victoria Wills

Ms. Victoria Elizabeth (Viki) Wills has been Director of Clinical Operations at BERGENBIO ASA since October 3, 2016. She brings over 30 years’ experience in the management of clinical programs from pharma, biotech and CRO companies across a number of therapeutic areas and phases, more recently focused on oncology. She qualified as a Pharmacist from Bath University and completed her post-graduate registration in Bristol, UK. She is Director of Mulberry Clinical Services Limited.

Debra Barker

Dr. Debra Debra, M.D. has been Non-Executive Director at BERGENBIO ASA since March 13, 2019. She is a seasoned clinical development executive with experience from Novartis, Roche, Smithkline Beecham and Knoll and served until recently as the Chief Medical and Development Officer at Polyphor Ltd. Dr Barker has a Diploma in Pharmaceutical Medicine and received a MSc in immunology from the King's College in London and a Medical Degree from the Queens College, Cambridge, UK.

Grunde Eriksen

Mr. Grunde Eriksen has been Non-Executive Director at BERGENBIO ASA since March 13, 2019. He is the founder and CEO of Altitude Capital AS, a private investment company established in 2016. Grunde is an experienced capital markets advisor and investor. He began his career in 1998 in Stockholms Enskilda Bank's ("SEB") corporate finance division in Stockholm before moving to the equity capital markets team in London. He then spent a further two years at SEB in Norway before joining Arctic Securities in 2007 as a partner working in equity sales.

Pamela Trail

Dr. Pamela A. Trail, Ph.D. has been Non-Executive Director at BERGENBIO ASA since March 13, 2019. She is CSO of Molecular Partners AG. Previously she held key strategic oncology leadership roles at Regeneron, MedImmune, Bayer Healthcare and BMS and served as CSO at Seattle Genetics. Dr. Trail received her Ph.D. from the University of Connecticut, Storrs, CT and was a postdoctoral Research Fellow at the Memorial Sloan-Kettering Institute for Cancer Research, NY

Stener Kvinnsland

Dr. Stener Kvinnsland has served as Non-Executive Independent Director at BERGENBIO ASA since September 1, 2015. Dr. Stener Kvinnsland has more than 30 years of experience in oncology. He is Chair of Board, Oslo University Hospital. Among Dr. Kvinnsland’s previous roles, he was Chief Executive Officer of the Bergen Hospital Trust (Helse Bergen), Head of the Department of Oncology and Medical Physics at Haukeland University Hospital, Professor of Medicine (Oncology) at the University of Bergen and Director Clinical R&D, Oncology for Pharmacia & Upjohn in Milan. He serves at Helse Stavanger Hf (chairman) and the Bergen Research Foundation (board member). Previously, he was employed at Oslo Universitetssykehus Hf (chairman) and Health Faculty at Tromso University (chairman).